OR5J2

Across TCGA pan-cancer cohorts, OR5J2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR5J2 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR5J2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR5J2 expression acts as an unfavorable survival marker.

SKCM, SCLC, and UCEC are the cancer types where OR5J2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	II,III,IV	0.232	0.567	.014	7	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	DFS	Median	All	0.171	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OR5J2–SKCM (DFS)

Open the SKCM breakdown →